C erebral venous thrombosis (CVT) is a rare cause of stroke with an incidence of ≈1.3 per 100 000 among adults. 1, 2 Unlike arterial stroke, CVT mainly affects young to middleaged adults and children, and >90% are <60 years. 3 Various risk factors for CVT have been identified, such as local infections of the head, acquired and genetic thrombophilia, and cancer, especially hematologic malignancies. Because of women-specific risk factors (oral contraceptives, pregnancy, and puerperium), CVT is 3× more common among women than among men.
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the Dutch Multiple Environmental and Genetic Assessment of Risk Factors for Venous Thrombosis (MEGA) study. The MEGA study is a case-control study performed in the Netherlands that included 4956 consecutive patients with a first deep-vein thrombosis of the leg or pulmonary embolism between March 1999 and September 2004. 15 Partners of patients were invited as control subjects and 3297 participated. An additional 3000 controls were recruited by random digit dialing. These participants were between the ages of 18 and 70 years and had no history of venous thrombosis. We excluded 4 cases and 3381 controls for whom no hemoglobin concentration was available. The excluded control subjects were mostly recruited after June 2002, when, for logistic reasons; blood sampling was no longer performed in the MEGA study. In cases, diagnosis of CVT was confirmed with computed tomography-venography, magnetic resonance imaging/magnetic resonance-venography, catheter angiography, or autopsy. Written informed consent was obtained from cases if plasma and DNA of the patient were stored. In patients for whom only clinical data were stored, informed consent was not obtained because this is not required under Dutch law. All controls from the MEGA study provided written informed consent.
Data Collection and Laboratory Measurements
Data on clinical manifestations, imaging, and outcome were recorded with a standardized case report form for cases. We extracted hemoglobin concentration and mean corpuscular volume (MCV) from the medical records. All laboratory measurements were done as a part of routine diagnostic work-up within 48 hours of admission. For laboratory measurements, a Sysmex XE-5000 Automated Hematology System (maximal imprecision ≤1.5%, inaccuracy, ±2%) was used for cases, and a Coulter MD-II Series Analyzer (maximal imprecision ≤2%, inaccuracy, ±2%) for controls.
Control subjects in the MEGA study completed a questionnaire with information on demographics, previous medical history, and risk factors for thrombosis. Blood was collected into vacuum tubes containing 0.106 mmol/L trisodium citrate and processed within 4 hours. The final concentration of hemoglobin was multiplied by a factor of 1.1 to adjust for the dilution by the trisodium citrate, as done previously.
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Definition of Anemia
We used the World Health Organization definitions for anemia: nonpregnant women hemoglobin <7.5 mmol/L, pregnant women <6.9 mmol/L, and men <8.1 mmol/L (http://www.who.int/vmnis/indicators/hemoglobin.pdf). Severe anemia is defined as hemoglobin <5.0 mmol/L for men and nonpregnant women or hemoglobin <4.3 mmol/L for pregnant women. Anemia is categorized as microcytic (MCV <80 fL), normocytic (MCV 80-100 fL), or macrocytic anemia (MCV >100 fL).
Data Analysis
We analyzed categorical data with the χ 2 test or Fisher exact test and continuous data with a Mann-Whitney test or Student t test, whichever was appropriate. The primary analysis was the difference in frequency of anemia between cases and controls. Results are given as percentages with absolute differences and 95% CIs. We used multivariate logistic regression analysis to adjust for potential confounding variables. CVT was used as a dependent variable. Anemia and hemoglobin concentrations (as a continuous variable) were used as independent variables in separate models. In each model, we adjusted for the following potential confounders: age, sex, malignancy, oral contraceptive use, and pregnancy/puerperium. We stratified the analysis for sex and MCV value. We also performed an analysis in which we divided subjects into those with normal hemoglobin (reference category), anemia, or increased hemoglobin. Increased hemoglobin was defined as >10.2 mmol/L for women or >11.5 mmol/L for men. In a subgroup analysis, we excluded patients with a history of malignancy. We also did a subgroup analysis in which we excluded cases with a recent infection or neurosurgical intervention, or who had a diagnosis of inflammatory bowel disease. We could not adjust for these potential confounders in the model because these conditions were not scored in the controls.
Results
Within the study period, 156 adult patients with CVT were admitted to our hospital. A total of 6297 control subjects participated in the MEGA study. After exclusion of subjects with missing baseline hemoglobin, 152 cases and 2916 controls were included in the analysis.
Cases were younger (mean age, 40 versus 48 years), more often women (74.3 versus 52.6%), and more often had been diagnosed with cancer (9.2 versus 3.7%) compared with controls ( Table 1) . Oral contraceptive use (69.7% versus 21.1%) and pregnancy/puerperium (5.3% versus 1.4%) were more frequent in female cases. The baseline clinical manifestations of patients with CVT are provided in Table 1 .
Mean hemoglobin concentration was lower in cases than in controls (8.06 versus 8.68 mmol/L; P<0.001; Table 2 ). Anemia was present in 27.0% (41/152) of the cases, significantly more frequently than in controls (6.5%; 189/2916; absolute difference, 20.5%; 95% CI, 14 to 28). Severe anemia was present in 2.6% of cases versus none in the controls (absolute difference, 2.6%; 95% CI, 1.0 to 6.6). Increased hemoglobin concentration was rare in both cases and controls (0.7 versus 0.2%; absolute difference, 0.5%; 95% CI, −0.8 to 1.8).
After adjustment for potential confounders, anemia was significantly associated with CVT (adjusted OR, 4.4; 95% CI, 2.8 to 6.9; Table 3 ). Similarly, hemoglobin concentration was inversely associated with CVT risk (adjusted OR per 1 mmol/L increase, 0.53; 95% CI, 0.42 to 0.66). Stratification by sex showed a stronger association between anemia and CVT in men (adjusted OR, 9.9; 95% CI, 4.1-23.8) than in women (adjusted OR, 3.6; 95% CI, 2.1 to 6.0). Stratification by MCV indicated that the risk of CVT was most clearly ). Finally, we divided subjects into those with normal hemoglobin (reference category), anemia, or increased hemoglobin. This stratification had no effect on the strength of the association between CVT and anemia (adjusted OR, 4.5; 95% CI, 2.9 to 7.0). Furthermore, it did suggest that increased hemoglobin was also associated with CVT (adjusted OR, 9.6; 95% CI, 1.0 to 90.7).
Discussion
In this case-control study, we found that CVT was significantly associated with anemia. Accordingly, we found a linear, inverse association between the risk of CVT and hemoglobin concentration. Subgroup analysis showed that the association was stronger in men and in patients with microcytic anemia. With a prevalence of 27%, the frequency of anemia among patients with CVT in our study is higher than has been reported before. In the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT), for instance, anemia was present in 9.2% of patients. 11 This discrepancy might be explained by the fact that the prevalence of anemia was not a specific research objective in ISCVT, and that measurement 10 We found a stronger association between CVT and anemia than a previous case-control study, despite a similar prevalence of anemia among cases. 13 Stolz et al 13 reported only a weak association with severe anemia (OR, 1.1) and no association with mild anemia. This difference is partly explained by the fact that in their study, the authors calculated separate ORs for mild and severe anemia, whereas in our main analysis, we determined the OR of any anemia (mild or severe) versus no anemia. Using our approach, the unadjusted OR for any anemia in the study by Stolz et al 13 would have been 2.8, which is in the same range as the unadjusted OR in our study (5.3) .
It is important to compare the prevalence of anemia in our control population to other studies that included healthy subjects. The US National Health and Nutrition Examination Survey determined the prevalence of anemia in noninstitutionalized civilians. 18 The prevalence in men aged 17 to 64 years, comparable with the age range of our control group, varied between 1.5% and 4.4%. The frequency of anemia among male controls in our study (3.3%) falls within this estimate. In women of similar ages, the prevalence was 6.8% to 12.2%, which is also comparable with the frequency we found (9.3%). A population-based study from Germany found a rate of anemia of 3.2% in men and women aged 45 to 74 years, 19 which is even lower than in our study. Therefore, we think that it is unlikely that an underestimation of the prevalence of anemia among controls biased our results.
Our data indicate that anemia is a stronger risk factor for CVT in men than in women. The most likely explanation for this discrepancy is the difference in absolute incidence of CVT, which is ≈2.5× higher in women than in men.
1 If anemia adds a similar absolute risk for CVT to the baseline risk in both sexes, the relative risk associated with anemia will be higher in the group with a lower absolute baseline incidence (ie, men). 20 Another contributing factor could be that men with CVT more often have an infection or a recent operation as a risk factor, and these conditions are also associated with anemia. 4 Finally, a lower risk of CVT among women with anemia might be related to the high prevalence of female patients who used oral contraceptives. Oral contraceptives are a well-known risk factor for CVT. 21 Some studies have found that these drugs also decrease the risk of anemia, which could result in a lower prevalence of anemia among women with CVT.
22,23 However, we adjusted for oral contraceptive use in our analysis, which makes this last explanation less plausible.
Although our study shows an association between anemia and CVT, this finding does not necessarily imply a causal relationship. Anemia could be an epiphenomenon of another underlying prothrombotic condition for which we were unable to adjust. Inflammatory bowel disease, infections, and neurosurgery, for instance, are all established risk factors for both CVT and anemia. 11, 24 Because information on these conditions was not available for controls, we could not include them in the multivariate model. To account for this limitation, we did a subgroup analysis in which we excluded cases with any of these conditions. Although attenuated, the association between CVT and anemia remained clinically relevant and statistically significant in this analysis. Nevertheless, we cannot exclude the possibility that other residual confounders had an effect on the analysis.
If a causal relation exists between anemia and CVT, it is interesting to speculate about the pathogenesis. Anemia, especially when caused by iron deficiency, can sometimes lead to thrombocytosis, which is a risk factor for venous thrombosis. 25, 26 This mechanism would be in line with the fact that we observed a stronger association between CVT and microcytic anemia because iron deficiency is the most important cause of microcytic anemia. Unfortunately, thrombocytes were not measured in the MEGA study, and thus we could not examine whether the presence of thrombocytosis modified the association between anemia and CVT. Iron deficiency has also been associated with an increased concentration of factor VIII, which is also a risk factor for thrombosis. 27 On the contrary, if either of these hypotheses were correct, anemia should probably also increase the risk of venous thromboembolism (deep-vein thrombosis of the leg and pulmonary embolism). Although there is some evidence supporting an association between venous thromboembolism and anemia, 28 anemia is generally not considered to be a risk factor for this condition. 29, 30 It is uncertain if the results of our study can be extrapolated to pediatric CVT. Children with CVT have other risk factors than adults, with an over-representation of infections and dehydration. 31 A previous study indicated that there may also be an association between iron deficiency anemia and CVT in children, but this study included only 6 patients with CVT. 32 Our data also suggest that increased hemoglobin is associated with CVT. Causes of increased hemoglobin include dehydration and polycythemia vera, both of which have been reported in patients with CVT. 31, 33 However, the degree of uncertainty of this observation is high because there was only 1 case with increased hemoglobin, and a larger sample size is required to confirm this finding.
Several limitations of our study warrant comment. First, although all cases were enrolled in a prospective study, the association between anemia and CVT was not a predefined research question. As a result, hemoglobin concentrations were missing in a small proportion (3%) of cases. Also, laboratory data that would have been helpful in determining the cause of anemia, such as ferritin, folic acid, and vitamin B12, were not available. However, we were able to categorize anemia according to MCV values, which provides a crude indication of the underlying cause. Second, cases and controls were not recruited in the same time period. The MEGA study recruited control individuals between 1999 and 2004, whereas the CVT cases were collected from 2006 to 2014. If the prevalence of anemia increased in those years, it could have biased the results. However, it seems unlikely that the extent of such a change in prevalence in such a short time period could be large enough to fully explain our findings. In fact, there is evidence that the prevalence of anemia among healthy women has decreased in the past decades. 34 Third, it would have been interesting to examine whether the association between anemia and CVT was influenced by the presence of thrombophilia. Unfortunately, this analysis was not possible because routine testing for thrombophilia was not done in cases. Finally, we were unable to calculate an adjusted OR for severe anemia because none of the controls had severe anemia. The fact that 4 of the 152 cases had severe anemia, compared with zero of the ≈3000 controls, indicates an association, but severe anemia may have been under-represented in controls. Severe anemia often leads to symptoms, and this may lead to reluctance to participate in a medical research study as a control subject. Still, even if severe anemia is a risk factor for CVT, our data suggest that it is not a common risk factor.
In summary, we found that anemia is associated with the occurrence of CVT. Anemia is a risk factor for both sexes, but the association was stronger in men than in women. 
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